Pelthos Therapeutics Inc. 8-K

What Happened
Pelthos Therapeutics announced two corporate governance actions in an 8-K filed May 21, 2026: its Audit Committee approved the dismissal of independent auditor CBIZ CPAs P.C., and the company entered a Separation and Release Agreement with former Chief Financial Officer Francis Knuettel II. The Audit Committee approved CBIZ’s dismissal on May 16, 2026, and the company informed CBIZ on May 18, 2026. Mr. Knuettel was terminated effective April 10, 2026, and the Separation Agreement was executed on May 15, 2026.

Key Details

• Auditor change: Audit Committee approved dismissal of CBIZ on May 16, 2026; company notified CBIZ on May 18, 2026. CBIZ’s audit report for year ended December 31, 2025, was unqualified and there were no disagreements or reportable events for 2024–2025 or through May 18, 2026.
• CFO separation date and pay: Francis Knuettel II’s employment terminated effective April 10, 2026; Separation Agreement dated May 15, 2026.
• Severance and equity: Company will pay $430,000 (12 months’ base salary) as separation pay, reimburse earned unpaid compensation and business expenses, and accelerate vesting of options and RSUs that would have vested during the 12 months following the separation date.
• Agreement terms: Separation Agreement includes customary release, confidentiality, non-disparagement and cooperation clauses, and becomes effective after a 7‑day revocation period following May 15, 2026. The agreement is filed as Exhibit 10.1.

Why It Matters
A change in independent auditor is material for investors because it affects who reviews and signs off on the company’s financial statements; here CBIZ was dismissed after issuing an unqualified audit for 2025 and noting no disagreements, which reduces immediate concern but warrants monitoring for the company’s replacement auditor and any transition impacts. The CFO departure and the separation package (cash payment and accelerated equity vesting) represent a near-term cash and potential equity expense for Pelthos and signal a leadership change in financial management. Investors should watch for disclosure of the new independent auditor and the company’s plan for filling the CFO role.